Ann: Suda completes $5.3m capital raising, page-2

Good morning all,
Interesting announcement.
I get that having money helps negotiating position but from the announcement they now say they need to run clinical trials in 2 of the sprays (001 and 003). You may say that they are not getting traction hence the need for trials (for FDA) and also they are not likely to partner soon. Thus left with midazolam and ondansetron, both interesting but smaller markets and still only in negotiation.

Also a 10% sale from current low SP.

Objectives (note the word) now includes "some key inflection points" over "next 12 months". Compare this to Decembers stated 2 deals done by end of 2014.

I am glad they have retained the ability to talk (ongoing discussions)!

I was hoping to sell the remaining small portion of my shares at high 4's. Don't like my chances now.

Note to self -"remain positive. Amongst the rubbish they tell us there may be hope."
Cheers all